In Brief: Sodium fluoride study
This article was originally published in The Tan Sheet
Sodium fluoride study: Final report of a trial on the treatment of osteoporosis with 25 mg sodium fluoride twice daily concludes that "slow-release sodium fluoride and calcium citrate administered for four years inhibits new vertebral fractures (but not recurrent fractures), augments spinal and femoral neck bone mass, and is safe to use." The randomized controlled study by researchers from the University of Texas Southwestern Medical Center and the Scott and White Clinic led by Charles Pak, MD, was published in the Sept. 15 Annals of Internal Medicine. Sodium fluoride is the subject of an investigational new drug application sponsored by the University of Texas Southwestern Medical Center, which holds the rights to the drug. Mission Pharmacal supplied the Slow Fluoride for the trial...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC